Drug intelligence / Profile preview

LY2382770

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LY2382770 is a humanized monoclonal antibody that specifically targets and neutralizes transforming growth factor beta 1 (TGF-β1). It was developed by Eli Lilly as an inhibitor of TGF-β1 signaling, a pathway implicated in fibrosis and inflammation. The drug was investigated primarily for the treatment of diabetic nephropathy and other kidney-related fibrotic diseases. Despite being well-tolerated in clinical trials, LY2382770 did not demonstrate efficacy in improving renal function or reducing proteinuria compared to placebo, leading to early termination of its phase II studies and discontinuation of development[2][3][4][7].

Other names: ANTI-HUMAN TGF-BETA1 IGG4 HUMANIZED MONOCLONAL ANTIBODY

Targets

TGFB1 (Transforming growth factor Beta-1 proprotein)

Beyond the preview

Go deeper on LY2382770.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY2382770.

Explore the full profile